Prescient Therapeutics (ASX:PTX) locks in OmniCAR cell manufacturing contract for clinical trials
Prescient Therapeutics (PTX) has signed a manufacturing services agreement with Q-Gen Cell Therapeutics to produce...
Prescient Therapeutics (PTX) has signed a manufacturing services agreement with Q-Gen Cell Therapeutics to produce...
Prescient has entered a deal with the manufacturing arm of the world-renowned QIMR Berghofer Medical...
During the second World War, scientists noted that soldiers exposed to nitrogen mustard gas developed...
Prescient Therapeutics Ltd (ASX:PTX) has entered into a five-year manufacturing services agreement with specialist cell therapy...
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has entered a services agreement with specialist cell therapy manufacturer...
Precedence Research suggests the global cancer therapeutics market size is predicted to surpass US$365.99 billion...
“The fact of the matter is there are people walking around now who shouldn’t be...
Clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX) has provided an upbeat update for the June 2022...
It’s quarterlies season as the ASX market announcements page becomes increasingly flooded with lodgements. The...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.